Identification and characterization of peptides from marine crustacean crabs and their bioactive properties; An approach to develop novel drugs for Alzheimer’s disease

Abstract

Abstract Peptide-based drugs have become the most promising drug therapy in the pharmaceutical industry. It accommodates a major part in treating diseases like neurodegenerative disorders, type 2 diabetes, blood pressure, etc. This study aims to isolate and characterize the marine peptides from the crustacean crab species named Scylla Serrata. The hemolymph was collected and subjected to thin-layer chromatography (TLC) and Fourier Transform Infrared spectroscopy for identifying amine groups. Further the peptide groups in the sample was confirmed by nuclear magnetic resonance analysis. Ultra-performance liquid chromatography (UPLC) for the crude was performed to identify the intensity of the peaks. The sample was further purified with Sephadex G-25 to elute the small molecular peptides. Antioxidant activity (DPPH) for the crude sample showed 55% of activity at 100µg/ml concentration and the fractions showed significant activity. The eluted fractions from the column chromatography were then subjected to SDS PAGE to identify the molecular weight of the peptides in which the peptide bands ranged between 75–100 kDa. Further, the best compounds must be developed as potential drugs for Alzheimer’s disease with an In-silico approach.